An Eight-Week Randomised, Double-Blind Study to Compare the Fixed-Dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy.

Trial Profile

An Eight-Week Randomised, Double-Blind Study to Compare the Fixed-Dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Amlodipine; Amlodipine/telmisartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms TEAMSTA-10
  • Most Recent Events

    • 23 Jun 2012 Planned number of patients changed from 756 to 2530 as reported by European Clinical Trials Database.
    • 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
    • 26 Jul 2010 European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA based on the results of this trial and TEAMSTA-5 and TEAMSTA Severe HTN, according to a Boehringer-Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top